Role of SST, CORT, and ghrelin and its receptors at the endocrine pancreas

Belén Chanclón1,2,3, Antonio J. Martinez-Fuentes1,2,3* and Francisco Gracia-Navarro1,2,3*

INTRODUCTION

The pancreas is a physiologically and biologically complex organ organized in exocrine and endocrine compartments which are modulated by a wide variety of neuronal and hormonal signals in an integrated manner. The exocrine function of the pancreas is performed by more than 90% of the whole pancreatic tissue and is essentially composed of acinar and ductal cells thatrespectively, synthesize and transport enzymes crucial for nutrient digestion at the gastrointestinal tract.

The endocrine function of the pancreas is in turn achieved by distinct cell types organized in major structures called islet of Langerhans, which are scattered throughout the organ and are in close contact with the vascular environment. At least five major different endocrine cell types have been described: glucagon-secreting alpha-cells, insulin-secreting beta-cells, somatostatin (SST)-secreting delta-cells, ghrelin-producing epsilon-cells, and pancreatic polypeptide-producing cells. The distribution and proportion of endocrine cells within the pancreatic islets varies between species (Jain and Lammert, 2009). The coordinated production, release, action, and relationship of the above-mentioned pancreatic endocrine peptides determine the constitutive metabolic homeostasis within the organism. In this sense, the endocrine dysfunction of the gland as the impairment of insulin production triggers the development of type 2 diabetes mellitus (T2DM) therefore, resulting in an abnormal regulation of blood glucose concentration with ulterior significant complications. It is widely known the close relationship between type 2 diabetes and obesity (Venables and Jeukendrup, 2009). In this sense, in fact, obesity is a multifactorial chronic metabolic condition that predispose to the development of T2DM and shares with the later a common feature: insulin resistance (Saltiel and Kahn, 2001). The increasing incidence of both metabolic disorders urges for the search of therapeutic targets in order to treat these pathologies and improve glucose homeostasis and insulin resistance, as well as body weight regulation. In this context, the action of the different ghrelin system components on glucose homeostasis, insulin resistance, and body weight regulation has been described and consequently, ghrelin system has been suggested as a potential drug target for the prevention or treatment of T2DM and obesity. In turn, some tissues are common targets of SST/cortistatin (CORT) and ghrelin (i.e., endocrine pancreas) and interestingly, these three molecules show a highly molecular parallelism (i.e., all peptides are processed from prepro-hormones that generate several biologically active peptides). In the present review, we analyze the literature relative to the modulation of endocrine pancreatic function by these two closely interrelated pleiotropic systems, SST/CORT, and ghrelin. Moreover, we also include its actions on glucose metabolism and insulin release as well as their possible pathophysiological role in metabolic disorders with increasing incidences as T2DM and obesity.

SST/CORT PLEIOTROPIC SYSTEM

Somatostatin was originally isolated from ovine hypothalamus based on its potent inhibitory action on pituitary growth hormone...
All five isoforms recruit several downstream transduction signals and this neuropeptide is also widely distributed, especially abundant in the cortex (where its name comes from), close to pharmacology, specifically, their comparable subnanomolar cyclic structure and the FWKT core (Phe7-Tyr8-Lys9-Thr10), a crucial motif for receptor binding. Thus, their differences are mediated via binding and activation of SST receptors, a family of five specific transmembrane proteins (named sst1–5) belonging to the superfamily of G proteins coupled receptors (GPCRs), and encoded by five distinct intronless genes (Gahete et al., 2010). All five isoforms recruit several downstream transduction signals upon SST binding such as adenyl cyclase and calcium channels, which are two major players involved in SST inhibitory action on hormone release. Similarly to SST tissue distribution, ssts are present in abundant tissue locations and often, in SST tissue targets, several isoforms are simultaneously present in the same cell. In this context, it has been reported that ssts functionally interact with each other and even with other GPCRs to form homo- and/or heterodimers that activate different signaling cascades and consequently mediate multiple biological actions (Moller et al., 2003).

The pleiotropic activity featured by SST fits well with both its ample tissue distribution and its multiple receptors. Moreover, it can also be likely related to the existence of a highly similar peptide of the same family, CORT, which was originally discovered in frogs and subsequently in rodents and humans (de Lecea et al., 1996; Tostivint et al., 1996). Like SST, CORT is the product of an enzymatically processed precursor, CORT propeptide, which shares high homology with SST precursor. SST and CORT precursors are encoded by two different genes that evolved from a common ancestral gene by a duplication mechanism (Tostivint et al., 1996; Gahete et al., 2010). Similar to that described for SST, processing of CORT precursor generates diverse mature peptides as CORT-14 and -29 in rodents and CORT-17 and -29 in humans. In addition, CORT- and SST-mature forms shares 11 aas, which can be further processed by the prohormone convertase 1/3 (PC1/3) thus generating the acylated-ghrelin in a proportion that depends on the study conditions. 

Ghrelin Pleiotropic System

The ghrelin gene, GHRL, encodes a 28-aa non-translated exon (Ex3), four coding exons (Ex1–4) and three introns, being a 28-aa native ghrelin peptide the predominant product of the 117-aa precursor pro-ghrelin (Kojima et al., 1999). Pre-ghrelin includes the signal peptide encoded by Ex1, and the coding sequence encoded by Ex2 and Ex3 which are the coding sequence of ghrelin (Seim et al., 2007). This transcript processing also generates different peptides or variants such as obestatin (of 23 aas), des-Glu14-ghrelin [matching to native ghrelin except for the deletion of one aa (Glu in the position 14)], etc. (Kineman et al., 2007; Seim et al., 2010).

Native ghrelin was originally isolated from the stomach of humans and rats based on its potent GH releasing activity (Kojima et al., 1999). Interestingly, native ghrelin has been the first natural hormone to be identified in which its third residue, usually a serine in mammals, contains the addition of a middle-chain fatty acid (n-octanoic acid) crucial for its biological activity. This post-translational modification is catalyzed by the ghrelin O-acyltransferase (GOAT; Gutierrez et al., 2008; Yang et al., 2008), a membrane bound O-acyltransferase located at the endoplasmic reticulum that uses fatty acids from the diet to fulfill its action (Kojima and Kangawa, 2005). Afterward, either acylated- or unacylated-ghrelin can be further processed by the prohormone convertase 1/3 (PC1/3) thus generating the acylated-ghrelin or its unacylated-ghrelin counterpart, a form of ghrelin initially considered as inactive (Zhu et al., 2006). Surprisingly, circulating unacylated-ghrelin levels are significantly higher than those of acylated ghrelin in a proportion that depends on the study considered (Hosoda et al., 2000; Yoshimoto et al., 2002; Broglio et al., 2004; Liu et al., 2008).

Frontiers in Endocrinology | Systems and Translational Endocrinology September 2012 | Volume 3 | Article 114 | 2

"fendo-03-00114" — 2012/9/15 — 14:12 — page 2 — #2
Acylated-ghrelin elicits its biological actions through the GH-secretagogue receptor type-1a, GHS-R1a, previously known as an orphan receptor that mediates the GH-releasing effect of synthetic GH-secretagogues, a group of peptide and non-peptide compounds with GH releasing properties. Currently, GHS-R1a is also called the ghrelin receptor based on the description of ghrelin as its natural ligand (Kojima et al., 1999).

The GHS-R gene consist of two exons whose transcription and processing originate two distinct forms of cDNAs: GHS-R1a, encoded by both exons, and a shorter form, GHS-Rib, derived from the exclusive transcription of the first exon (Howard et al., 1996; Kojima and Kangawa, 2005). The full-length of human GHS-R1a is a highly conserved protein of 366 aas that belong to the GPCR family containing seven putative membrane spanning alpha-helical segments and three intracellular and extracellular loops (Howard et al., 1996). GHS-R1a specifically recognizes the binding of acylated-ghrelin but not that of unacylated-ghrelin, whose specific receptor remains to be identified. In contrast, GHS-Rib isoform is an alternatively truncated variant of 289 aas that only possesses the first five transmembrane domains of GHS-R1a (Howard et al., 1996; Kojima and Kangawa, 2005), and it was considered, until recently, to be a non-functional GHS-R isoform based on its inability to bind acylated-ghrelin. Interestingly, it has been recently described the interaction of GHS-Rib with GHS-R1a and other receptors to form heterodimers (Muciseti et al., 2007), as well as the heterodimerization of GHS-R1a with SST and dopamine receptors (Sinm et al., 2010).

In terms of signal transduction, it has been described that GHS-R1a activation involves the participation of several signaling cascades including phospholipase C (PLC), protein kinase C (PKC), protein kinase A (Kojima and Kangawa, 2003) intracellular and extracellular Ca2+, and mitogen-activated protein kinases (Moussaou et al., 2006; Camina et al., 2007).

Different components of the ghrelin system have been found to be ubiquitously represented in the organism. Specifically, ghrelin was originally described to be predominantly produced by endocrine cells of the stomach submucosa (Kojima et al., 1999). In addition, it was also documented to be produced at other portions of the gastrointestinal tract from the stomach to the colon and in a wide variety of peripheral tissue such as the pancreas (Kojima et al., 1999; Date et al., 2008). It has also been showed the expression of ghrelin at different locations of the central nervous system (Ueberberg et al., 2009). The wider ghrelin tissue distribution is mimicked by that of GOAT, particularly in major ghrelin-secreting tissues (Gutierrez et al., 2003; Yang et al., 2008; Sakata et al., 2009) although GOAT transcripts appear to be much lower expressed than ghrelin transcripts. However, it has been documented that a small proportion of ghrelin expressing cells devoid of GOAT expression thus suggesting and supporting that unacylated-ghrelin might show independent biological actions to that described for acyl-ghrelin, most probably through its coupling to a still unknown receptor different from GHS-R1a, as it has been recently suggested and documented (Toshini et al., 2006; Lue et al., 2010; Toglitto et al., 2010). Moreover, regulation of unacylated-ghrelin secretion under food restriction condition has been reported, thus supporting a not passive role for this unmodified peptide (Kirchner et al., 2009).

Regarding obestatin, this 23-aa peptide is mainly produced in the stomach and at lower level in the pancreas, spleen, testis, duodenum, jejunum, colon, and mammary gland (Ren et al., 2009). To date, although obestatin receptor remains unknown, it has been proposed that GPR39 or glucagon-like peptide-1 receptor might be potential receptors for obestatin (Granata et al., 2008; Ren et al., 2009).

**Actions of SST/Cort System at the Endocrine Pancreas**

Somatostatin has long been known to potently modulate pancreatic function by playing a regulatory role on insulin and glucagon secretion. This tight regulation is accomplished by the coordinated action of SST biologically active forms. In this sense, SST-14 is the major product released by adult pancreatic delta-cells, whose contribution to total circulating SST accounts for nearly 90%. SST-14 immediate actions imply the paracrine regulation of other pancreatic endocrine cells. In addition, endocrine pancreatic function is...
also under the control of the major circulating SST form, SST-28. In this context, it has been documented that SST-14 and SST-28 differently target pancreatic alpha- or beta-cells. Accordingly, SST-14 has been associated with the inhibition of glucagon secretion while SST-28 seems preferentially to inhibit insulin secretion (Strzowski and Blake, 2008). In either case, inhibitory action of SST on both insulin and glucagon release would contribute to preserve glucose homeostasis which, in turn, retrogradely regulates SST plasma concentration. For this reason, during fasting, plasma SST level is low and increases up to twofold after meals. In such hyperglycemic conditions, insulin induces SST release and consequently shuts down its own release as a protective mechanism to prevent a rapid hypoglycemia at the post-prandial state. In contrast, SST release is also increased at low plasma glucose concentration as a consequence of the coordinated action of glucagon and L-glutamate, a co-secretion product of alpha-cells (Strzowski and Blake, 2008).

The SST action on pancreatic hormones is mediated by its interaction with the different receptor isoforms, however, conflicting data about receptor expression at the pancreatic level have been published which, might be related with the different method used and/or species analyzed. In general, it is likely that endocrine pancreas expresses all five sst isoforms, being probably sst1, sst2, and sst5 those expressed in a predominant manner. Specifically, it has been demonstrated by RT-PCR that rodent pancreas expresses all sst isoforms except sst4. In turn, by double immunohistochemistry methods, it has been confirmed the expression of sst2 and sst5 in both rodent beta- and delta-cells. In humans, it has been reported a predominant expression of sst2 in alpha-cells, sst1 and sst5 in beta-cells, and sst5 in delta-cells while there is not consistent data on the expression of the rest of ssts (Strzowski and Blake, 2008; Gaetche et al., 2010).

In addition, and in order to ascertain the subtype receptors underlying the inhibitory effect of SST on pancreatic hormones, specific receptor agonists, and antagonists as well as knock out mouse models with deletion of the different ssts isoforms have been employed. These issues have been amply revised elsewhere (Strzowski and Blake, 2008) and briefly, it appears that sst2 seems to mediate glucagon inhibition and sst5 looks as the main receptor mediating insulin inhibition in rodents. More recently, high expression of sst5 has been also demonstrated in mouse pancreatic islets (Regard et al., 2008). In human, by contrast, sst2 looks to be the main receptor mediating both insulin and glucagon release, although sst1 and sst5 also participate in the regulation of insulin secretion (Gaetche et al., 2010). In summary, several sst isoforms would mediate the inhibitory action of SST on insulin and glucagon secretion through a mechanism that indubitably is species-dependent, and will essentially depend on the receptor expression pattern. In relation to CORT and its role on pancreatic function, only a few studies are available. Particularly and similarly to SST, CORT expression has been reported at the endocrine pancreas and essentially mimics its inhibitory action on insulin secretion under physiological and certain pathological conditions (Grottoli et al., 2006; Breglio et al., 2008), although the molecular mechanism underlying such inhibitory action is still unclear. In addition, it should be highlighted that CORT is also able to elicit distinct functions to that showed by SST mainly through its coupling to the ghrelin receptor (GHS-R1), as it has been recently documented for others endocrine secretions (Cordoba-Chacon et al., 2011).

**ACTIONS OF GHRELIN SYSTEM AT THE ENDOCRINE PANCREAS**

After ghrelin discovery, it was reported that pancreatic epsilon-cells are the major source of ghrelin forms during fetal life until early post-natal period (Wierup et al., 2002; Chanose and Wong, 2004). After this period, the major source of ghrelin production is the stomach submucosa (Kojima et al., 1999) while, the pancreas turns on a secondary source of ghrelin production with low level of ghrelin receptor expression (Veldhuis and Bowers, 2010). At the pancreas, the major source of ghrelin resides into epsilon-cells (Wierup et al., 2002, 2004; Prado et al., 2004) although it appears that is also produced by beta-cells in humans (Volante et al., 2002) and by glucagon-producing alpha-cells in human and rats (Date et al., 2002). In any case and in terms of ghrelin production, it has been described that during adult life the 65–90% of circulating ghrelin corresponds to that synthesized and released by the stomach, being the rest derived from other tissues including the pancreas and the intestine (Al Massadi et al., 2011).

Endocrine ghrelin actions at the pancreas involve inhibition of SST release by delta-cells, and stimulation of glucagon release by alpha-cells (Quder et al., 2009, 2008; Veldhuis and Bowers, 2010; Chuang et al., 2011) as well as inhibition of pancreatic polypeptide release by PP cells (Quder et al., 2008; Kumar et al., 2010), being all cells types in which GHS-R expression has been documented (Wierup et al., 2002, 2004; Kageyama et al., 2005; Dezaki et al., 2008; Granata et al., 2010a). On the other hand, SST and glucagon have also been shown to elicit a reciprocal modulation of ghrelin production (Figure 2). Furthermore, it has been reported that insulin and SST inhibit ghrelin release while glucagon inhibits its secretion in rodent although stimulate ghrelin release in humans (Quder et al., 2008).

Although ghrelin effect on insulin secretion is supported by an increasing number of reports, its precise role is nevertheless controversial since either stimulatory or inhibitory actions has been reported depending on the ghrelin doses used and/or experimental conditions employed as recently reviewed by Granata et al. (2010a,b). Specifically, the ghrelin stimulatory effect of insulin release is mainly mediated by an increase of cytosolic Ca2+ upon GHS-R activation, while the participation of a different receptor has been proposed based on the observed stimulatory action of both acylated- and unacylated-ghrelin on insulin release in a hamster beta-cell line devoid of GHS-R expression (Granata et al., 2007). In addition, it has also been described that ghrelin administration increases insulin release in rats under conditions of low blood insulin as a consequence of a 90% pancreatectomy (Keren et al., 2009). Reciprocally, insulin inhibits ghrelin expression (Veldhuis and Bowers, 2010) and more recently it has been proposed that insulin might act as an inhibitor of pancreatic ghrelin activation by inhibition of GOAT expression (An et al., 2011). In clear contrast to the above stimulatory role of ghrelin on insulin secretion, the ghrelin inhibitory action has been prevalently reported and examined in several biological and animal models...
including cultured pancreata, cultured islets and heterologous cell models (Granata et al., 2010a; Dezaki et al., 2011), as well as by using several methodological approaches. Overall, it has been described that ghrelin administration significantly reduces insulin secretion (Broglio et al., 2001; Tong et al., 2010), and this action was blocked in the presence of a higher dose of unacylated-ghrelin, suggesting the participation of a receptor distinct to GHS-R on insulin secretion modulation (Qader et al., 2008). Reduction of insulin level by ghrelin administration triggers a concomitant elevation of blood glucose levels in a dose-dependent manner as well as deterioration of insulin sensitivity during glucose tolerance, as it has been described in both humans and rodents (Korbounis and Grossman, 2004; Dezaki et al., 2008; Tong et al., 2010; Sato et al., 2012). The hyperglycemic action of ghrelin, but not by unacylated-ghrelin in rodents, was blocked by simultaneous administration of GHS-R antagonist thus revealing the specific participation of GHS-R in the hyperglycemic role of ghrelin (Dezaki et al., 2008). In addition, GHS-R deletion also reduces blood glucose level and significantly enhances insulin sensitivity (Longo et al., 2008; Qi et al., 2011). Importantly, the involvement of GH (a long time known hyperglycemic hormone) has been excluded from the hyperglycemic effect of ghrelin administration based on elevated plasma glucose levels observed in response to eugonous ghrelin administration in GH-deficient mice (Dezaki et al., 2008) and subjects with GH-deficiency (Vestergaard et al., 2008). Similarly, ghrelin hyperglycemic effect have been reported to be independent of an insulin resistance induction as evidenced by insulin and glucose tolerance tests after ghrelin administration (Dezaki et al., 2008).

In order to ascertain whether the insulinostatic action of ghrelin is due to the peptide derived from the stomach or other sources as the pancreas, GHS-R antagonist was administered to gastrectomized animals and a significant increase in insulin secretion was observed in a similar extend to that observed in normal rats. This observation suggests that intra-islet ghrelin may locally act on insulin production regulation (Dezaki et al., 2007). However, Bando et al. (2012) recently reported that intra-islet ghrelin does not play a major local role on the regulation of insulin release in vivo, based on their findings on transgenic mice in which ghrelin and GOAT were overexpressed in beta-cells. The discrepancy between these two later studies may reside on the different ghrelin concentration reached at the surrounding microenvironment of beta-cells.

In addition to the regulatory role of ghrelin on pancreatic function, it has also been described that acylated- and unacylated-ghrelin as well as obestatin elicit a protective role by preventing apoptosis on pancreatic islet in rodents, humans, and several beta-cell lines (Granata et al., 2012b). In this sense, it has been reported that beta-cell destruction elicited by streptozotocin administration was precluded by ghrelin by increasing both beta-cell mass and insulin release in rats (Irafo et al., 2006). Furthermore, ghrelin and obestatin also protect against apoptosis induced by serum starvation and cytokines in both human islets and beta-cell lines (Granata et al., 2007, 2008, 2010a). In well agreement with this, ghrelin and obestatin exert their mitogenic effect by increasing the number of beta-cells in 90% pancreati-tomized rats (Kerem et al., 2009) and in a hamster beta-cells line (Granata et al., 2010a), proliferative action that was blocked by administration of ghrelin antagonist or ghrelin antibody (Kerem et al., 2009; Granata et al., 2010a). These findings suggest that a cross-talk between ghrelin and obestatin may exist (Granata et al., 2008).

**ROLE OF SST/CORT SYSTEM IN T2DM AND OBESITY**

They are not many reports on the role of SST/CORT in situations with altered metabolic conditions. In this sense, an increase in the number of SST-producing cells in T2DM patients has been recently described, although circulating SST remains in the same level to that depicted by control subjects. However, in an experimental model of obese and spontaneously diabetic mice, SST content is significantly increased (Strowski and Blake, 2008). In this scenario, the well established inhibitory actions of SST on pancreatic function, particularly on insulin and glucagon secretion (Figure 1) as well as its inhibitory action on intestinal glucose absorption, predicted its use as a key tool to potentially regulate glucose homeostasis and insulin sensitivity in diabetes and obesity (Hansen et al., 2004; Tsotzas et al., 2008). Indeed, initial studies evaluated SST role on insulin hypersecretion as well as in hyperinsulinemia associated with obesity, two conditions that were described to induce insulin resistance (Jansen and Oberg, 1999; Boehm, 2003). Consequently, significant reductions in body weight and insulin release as well as an improvement of insulin sensitivity were observed in obese patients treated with synthetic SST analogs (Boehm and Lustig, 2002; Velasquez-Mayer et al., 2004; Lustig et al., 2006; Tsotzas et al., 2008), which were originally developed as a consequence of the SST short half-life. Similarly to SST, it has also been reported an inhibitory action of CORT on insulin release in patients with acromegaly or prolactinoma (Grotoli et al., 2005). In relation to CORT, and based on its described anti-inflammatory properties, it would be of interest to explore its role on the inflammatory signaling that occurs during obesity conditions.
More recently, the effect of a multi-ligand SST analog (pasireotide) on hormones that mediate glucose homeostasis has been described in healthy volunteers (Golor et al., 2012; Shenouda et al., 2012). Accordingly, based on the high binding affinity for four of the five SST receptor subtypes (sst1-3, and sst5) elicited by pasireotide, it has been administered to healthy subjects and an elevation of blood glucose has been observed mainly as a consequence of its inhibitory action on both insulin and glucagon release (Shenouda et al., 2012). Similar hyperglycemic effect of pasireotide has been observed in clinical trials in which pasireotide administration was evaluated on patients with endocrine pathologies as Cushing’s disease, acromegaly, and neuroendocrine tumors (NETs). In these pathologies, hyperglycemia might be further worsened in base to their inherent hormonal nature (Boscaro et al., 2009; Petersenn et al., 2010; Colao et al., 2012). Furthermore, hyperglycemia persists even when cortisol level declines by administration of SST analogs, i.e., pasireotide as it has been recently reported (Colao et al., 2012).

In sum, hyperglycemia conditions occur in an elevated proportion of individuals suffering of acromegaly. Cushing’s disease or NET and accordingly, it has been proposed that regular blood glucose testing and insulin analogs will be required, particularly when SST analogs are therapeutically used in these pathologies (Resmini et al., 2009; Colao et al., 2012).

**ROLE OF GHERLIN SYSTEM IN T2DM AND OBESITY**

As mentioned earlier, a growing body of studies supports the inhibitory role of ghrelin on insulin release in vivo and in vitro and its influence on glucose tolerance. Accordingly, it has been proposed that the antagonism of ghrelin system components could improve glucose homeostasis and/or beta-cell function under certain metabolic disorders as T2DM, a complex disease with a strong genetic, behavioral, and environmental background that is characterized by two distinctively conditions: insulin resistance and progressive beta-cell dysfunction. In T2DM, beta-cells become unable to adequately increase insulin release to compensate insulin resistance and consequently leading to a situation of hyperglycemia. It is well known the close association between T2DM and obesity in terms of metabolic imbalance and their common features, insulin resistance, in which ghrelin system could be of relevance based on its ability to modulate both glucose homeostasis and weight loss (Eiser et al., 2007).

Under normal metabolic conditions, circulating ghrelin and plasma glucose concentrations are inversely related. In fact, ghrelin levels are increased under fasting conditions or immediately before meals and significantly decreased after feeding (Angelidis et al., 2010). Obviously, the meal-related pattern of ghrelin is also opposite to that depicted by insulin and consequently the fall of ghrelin at post-prandial state has been argued to partially depend on the rise of insulin release after food intake (Solomon et al., 2008). Accordingly, the tight relationship between ghrelin and insulin also relies in the general assumption that insulin elicits a negative action on both plasma acylated- and unacylated-ghrelin concentration (Saad et al., 2002; McLaughlin et al., 2004), while administration of acylated-ghrelin results in insulin resistance (Gauna and van der Lely, 2003).

In subjects affected by T2DM and consequently resistant to insulin, it has been showed that blood ghrelin concentration was chronically lower than that observed in healthy subjects even when
Schellekens et al., 2010; Briggs and Andrews, 2011). Another set of intake, and ultimately inducing weight loss (Wortley et al., 2005; ods ameliorate obesity condition by reducing appetite or food pharmacological approaches to block or neutralize either ghrelin conditions (i.e., insulin resistance). Thus, some studies evaluated addressed in order to promote weight loss and to improve obesity cological, immunological, and genetic approaches have been ever, the underlying molecular mechanisms of these actions have been used to promote weight loss and to improve obesity (i.e., insulin resistance). Thus, some studies evaluated pharmacological approaches to block or neutralize either ghrelin or its receptor under diet-induced obesity and how these methods ameliorate obesity condition by reducing appetite or food intake, and ultimately inducing weight loss (Wortley et al., 2005; Schellekens et al., 2010; Briggs and Andrews, 2011). Another set of age, sex, and body mass index (BMI) were adjusted, probably as a direct effect of insulin on ghrelin-producing cells (Poykio et al., 2003; Angelidou et al., 2010; Verbalis and Depoortere, 2012). Based on the influence of ghrelin on insulin release and glu cose homeostasis, it has been suggested that ghrelin antagonism could be of interest to treat T2DM and related metabolic patholo gies. In this context, it has been shown that deletion of ghrelin gene promotes insulin release and ameliorates glucose intoler ance and hyperglycemia in a diabetic and obese mice model (Sun et al., 2006). In well agreement with this, GHS-R ablation also improves insulin sensitivity (Gomez et al., 2009). Likewise, it has also been documented an improvement of glucose homeosta sis in streptozotocin-induced diabetic rats treated with obstetin (Granata et al., 2010b) as well as a reduction in insulin resistance in mice fed with a high fat diet (Granata et al., 2012a).

On the other hand, obesity conditions have been associated with some ghrelin and GHS-R gene variations although some dis crepancies exist depending on studies and population considered (Pantel et al., 2006; Liu et al., 2007; Ukkola, 2011). In this sense, available data are still inconclusive and might be limited by some relatively small analyzed cohorts that might restrict the power of association. However, it has been well documented that under obesity con ditions plasma ghrelin levels negatively correlate with BMI and consequently with factors or parameters that are elevated in obe sity such as insulin, leptin, and fat mass (Tschop et al., 2001). In this sense a chronic lower ghrelin plasma concentration in obese children and adults has been reported in comparison with those of age-matched lean controls (Tschop et al., 2001; Reinherz et al., 2008; Schellekens et al., 2010). Similar data have been cited for Pima Indians, a population reported with the highest prevalence rates of obesity and T2DM when compared with Caucasians (Tschop et al., 2001). Similarly to that reported under normal metabolic condi tion, ghrelin also elicits a meal-related pattern although under obesity conditions the fall of ghrelin level at post-prandial state is less pronounced. Such downregulation might be a consequence of elevated fasting insulin or leptin levels observed in obesity (Baragli et al., 2011). In this sense, it has also been suggested that the decreased secretion of ghrelin, could be responsible for the concomitant decreased levels of circulating GH observed in obese individuals (Maccario et al., 2000; Tschop et al., 2001). More recently, the decreased ghrelin concentration observed in obesity could be an adaptive mechanism to maintain energy homeostasis has also been proposed (Tschop et al., 2001). In rodents, dimin ished ghrelin levels have been found at tissue level as well as a significant reduction in plasma ghrelin concentration and synthe sis in obesity conditions induced by diet (Sahin et al., 2011; Aydin et al., 2012).

Targeting ghrelin system components by different pharma cological, immunological, and genetic approaches have been addressed in order to promote weight loss and to improve obesity conditions (i.e., insulin resistance). Thus, some studies evaluated pharmacological approaches to block or neutralize either ghrelin or its receptor under diet-induced obesity and how these methods ameliorate obesity condition by reducing appetite or food intake, and ultimately inducing weight loss (Wortley et al., 2005; Schellekens et al., 2010; Briggs and Andrews, 2011). Another set of studies, examined the protection of ghrelin system against rapid weight gain by exposure to a high fat diet by knocking out either ghrelin (Wierley et al., 2009) or GHS-R (Castaneda et al., 2010). In these studies, an improvement of glucose tolerance was observed even though there is no effect on body weight (Zigman et al., 2005; Longo et al., 2008). Similar data were obtained in a genetically obese mice model (ob/ob; leptin deficient) in which the improve ment of insulin sensitivity and glucose homeostasis was attributed to ghrelin although the obese phenotype remains unchanged (Sun et al., 2006).

In addition, it has also been proposed that GOAT by a spe cific inhibitor could be a potential treatment against obesity by inhibiting ghrelin acylation and consequently avoid weight gain (Gualillo et al., 2008; Yang et al., 2008; Gomez et al., 2009; Barnett et al., 2010).

On the other hand, diet-induced weight loss elicits an increase in circulating ghrelin levels thus normalizing them until near opti mal concentration, rise that probably may hamper the sustained weight loss (Cummings et al., 2002; Hansen et al., 2002). In cases of morbid obesity, a more drastic method as bariatric surgery has been employed in order to reduce metabolic complications associated to obesity. Interestingly and contrary to that reported in diet-induced weight loss, after bariatric surgery ghrelin level significantly decreases and insulin sensitivity is rapidly restored, thus improving the associated diabetic state (Beckman et al., 2010; Hillman et al., 2011). In this context, sustained low ghrelin level reached by this surgical procedure precludes or delays weight gain by reducing hunger, an effect that is not observed in procedures as weight loss by diet modification in which ghrelin levels gradually normalizes with a consequent weight gain. On the other hand, in morbid obese patients, it has been suggested that equimolar administration of acylated- and unacylated-ghrelin also improve insulin sensitivity (Kiewiet et al., 2009).

Unfortunately, there is not yet a ghrelin system based therapy that ensures a sustained weight loss, although ghrelin antagon is and/or GOAT inhibitors may be considerate good therapeutic candidates for the treatment of T2DM and obesity.

CONCLUSION

The complex relationship of ligand–receptor architecture of SST/CORT and ghrelin systems is complemented by the func tional relevance of their common tissue targets. Indeed, besides their opposite influence on GH release at the pituitary level, SST/CORT and ghrelin systems act on the same cellular tar get to influence common and relevant biological actions as it is the case of their interactions on beta cell function and survival as well as on glucose homeostasis and insulin resistance. How ever, the underlying molecular mechanisms of these actions have not been fully elucidated yet. Interestingly, different and severe metabolic dysfunctions as T2DM and obesity have been described to modulate their circulating levels and the expression of some components of both systems at hypothalamic, pituitary, or pan creatic level. In sum, there are an increasing number of evidences that support a potential contribution of SST/CORT and ghre lin system components in the endocrine pancreas dysfunction in prevalent neuroendocrine-metabolic pathologies (T2DM and obesity) which suggest that these systems could be considered as
future valuable therapeutic targets for the prevention or treatment of such metabolic disorders. In this sense, future research will be of particular importance in order to determine whether SST/CORT and ghrelin systems and their receptors will act at pancreatic islets under physiological and pathological conditions. Likewise, the underlying molecular mechanisms as well as the precise role and the contribution of islet-derived -CORT, and -ghrelin in the pancreatic endocrine deregulation and/or the resulting insulin resistance under severe metabolic conditions should be investigated.

REFERENCES

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

References of such metabolic disorders. In this sense, future research will be of particular importance in order to determine whether SST/CORT and ghrelin systems and their receptors will act at pancreatic islets under physiological and pathological conditions. Likewise, the underlying molecular mechanisms as well as the precise role and the contribution of islet-derived -CORT, and -ghrelin in the pancreatic endocrine deregulation and/or the resulting insulin resistance under severe metabolic conditions should be investigated.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.

Brazeau, P., Vale, W., Burgus, R., Galy, M. E., and Ozercan, M. R. (2012). Examination in pancreatic islets. J. Physiol. Endocrinol. Metab. 36, 883–889.

Asakawa, A., Inui, A., Kaga, T., Yuzuriha, An, W., Li, Y., Xu, G., Zhao, J., Xiang, Al Massadi, O., Tschop, M. H., and Baragli, A., Lanfranco, F., Allasia, S., Bando, M., Iwakura, H., Ariyasu, H., Barnett, B. P., Hwang, Y., Taylor, M. S., and Leahy, D. J., Hussain, M. A., Tschop, M. H., Boeke, J. D., and Cole, P. A. (2012). Use of somatostatin receptor analog pasireotide (SOM230): a multicenter, phase II trial. Neuroendocrinology 94, 115–122.
Golor, G., Hu, K., Ruffin, M., Gauna, C., and van der Lely, A. J. (2005). Fieffe, S., Morange, I., Petrossians, P., Chanclón et al. SST/CORT and ghrelin in endocrine pancreas. Endocrinology 146, 512–529.

Granata, R., Settanni, F., Gallo, D., Tovarri, L., Biancone, L., Cantaluppi, V., Nano, R., Annunziata, M., Campana, P., Argiropoli, E., Ghe, C., Volante, M., Papetti, M., Mascioli, G., and Ghigo, E. (2008). Obestatin promotes survival of pancreatic beta-cells and human islets and reduces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 57, 967–975.

Gottlieb, S., Celleno, R., Gase, V., Pronelde, L., Carramato, B., Rea, T., Ragnazi, F., Pignata, F., Albetti, D., Ferrara, B., and Angioli, G. (2005). Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J. Endocrinol. Invest. 28, 973–980.

Granata, R., Baragi, A., Celleno, R., Scaraffa, F., and Ghigo, E. (2010). Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J. Med. Chem. 53, 107–118.

Granata, R., Volante, M., Settanni, F., Gauza, C., Ghis, C., Annunziata, M., Drida, R., Gesmundo, L., Abrah, T., Van Der Ley, A. J., Mascioli, G., Ghigo, E., and Papetti, M. (2013). Unacylated ghrelin promotes islet cell mass and prevents diabetes in streptozotocin-treated norad rats. J. Med. Chem. 45, 9–17.

Granata, R., Gallo, D., Laque, R. M., Baragi, A., Scaraffa, F., Grande, C., Gesmundo, L., Carbone-Chacon, L., Bergandi, L., Settanni, F., Tagliantis, G., Volante, M., Gianotti, S., Annunziata, M., Chanele, B., Carpentieri, E. Rocchero, S., Matea, D., Gera, M., Parazzini, F., Di, H., Camus, G., Carstoi, J. P., Papi, M., and Ghigo, E. (2012). Obestatin regulates adipocyte function and protein against diet-induced insulin resistance. FASEB J. 26, 5383–5391.

Granata, R., Settanni, F., Scarazzini, M., Nano, R., Tagliafico, G., Trombetta, A., Gallo, D., Puntoni, L., Burali, M. F., Abrah, T., Van Der Ley, A. J. and Ghigo, E. (2012). Dynamic ghrelin fragments and analogs promote survival of pancreatic beta-cells and human pancreatic islets and prevent diabetes in streptozotocin-treated rats. J. Med. Chem. 55, 2382–2396.

Granata, R., Settanni, F., Biancone, L., Tovarri, L., Nano, R., Bertani, E., Destefano, S., Annunziata, M., Marinetti, M., Catapano, G., Chere, G., Iaccarino, P., Dreon, M., Pangione, B., D’Amico, L., and Mascioli, G. (2007). Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets. J. Mol. Endocrinol. 38, 395–408.

Ghatei, M. A., Small, C., and Bloom, S. R. (2002). The tissue distribution of the somatostatin and cortistatin two sibs: their use in the treatment of endocrine disorders. J. Clin. Endocrinol. Metab. 87, 128–134.

Navarro, F., Luque, R. M., and Martinez-Fuentes, A. J., Gracia-Beltran, F., Vargas, G., Sosa, E., Ramirez, E., Gonzalez-Rey, E., and Delgado, M. (2008). Emergence of cortistatin as a new drug target in the treatment of acromegaly or prolactinomas: an open-label, multicenter, non-comparative study. J. Endocrinol. Invest. 28, 127–131.

Gonzalez-Rey, E., and Delgado, M. (2008). Acylation of ghrelin in the endocrine pancreas. Diabetologia 51, 148, 5175–5185.

Isgaard, J., and Granata, R. (2011). Ghrelin in cardiovascular disease and atherosclerosis. Mol Cell Endocrinol. 349, 59–64.

Iann, R., and Lammerz, E. (2009). Ghrelin receptors and their use in the treatment of endocrine disorders. World J. Gastroenterol. 15 Suppl. 1, 159–167.

Ismo, E., and Obegh, K. (1999). Somatostatin receptor ligands and their use in the treatment of endocrine disorders. Curr. Pharm. Des. 5, 695–725.

Jaworek, A., Bolanowski, M., Syrjka, J., Budzisz-Tapiekska, G., Kulkos, M., Kolodziejczyk, A., and Dradowska, A. (2012). Effective therapy of insulinomas by using long-acting somatostatin analogs. A case report and literature review. Exp. Clin. Endocrinol. Diabetes 120, 62–67.

Jeffery, P. R., Meguid, M. A., and Lin- don, S. R. (2011). Endocrine impact of Helicobacter pylori focus on ghrelin and ghrelin-"yarbenovitro": World J. Gastroenterol. 17, 1249–1256.

Kadoglou, N. P., Salee, N., Kapilovitz, A., Langenbroos, S., Vettia, I., Kontakis, A., and Lapou, C. D. (2012). Effects of atorvastatin on apolipoprotein, insulin, ghrelin and ghrelin-9 in patients with type 2 diabetes. Acta Diabetol. 49, 269–276.

Kapczynska, H., Funabashi, H., Hayama, M., Takeuchi, F., Kita, K. and Goto, Y. (2011). Somatostatin receptor ligands and their use in the treatment of endocrine disorders. Curr. Pharm. Des. 5, 695–725.
Kumar, R., Salehi, A., Rehfeld, J. F., Korbonits, M., and Grossman, A. B. (2009). Kineman, R. D., Gahete, M. D., and Kirchner, H., Gutierrez, J. A., Solen-Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul. Pept. 158, 27–31.

Kesmez, M., Salman, S., Ozyay, S., Paasoglu, H., Bekteli, A., Hastooglu, R., and Yilmaz, T. U. (2009). Exogenous ghrelin enhances endocrine and exocrine regeneration in pancreaticoduodenal trauma. J. Gastrointest. Surg. 13, 775–781.

Kiewiet, R. M., van Aken, M. O., van der Weerd, K., Uitterlinden, P., Themmen, P. N., Hoglund, P., Lindstrom, E., and van der Woude, K. (2004). Ghrelin: update on a novel hormone system. Eur. J. Endocrinol. 151, S1–S12.

Kim, S. Y., Fujii, H., Takahashi, A., Taguchi, M., Mitakawa, M., Ohara, K., Yamada, S., and Takeichi, Y. (2011). Impaired ghrelin metabolism in mice lacking both ghrelin and its receptor is restored after successful surgical pancreatitis if pancreatic (beta-cell) function is preserved. Eur. J. Endocrinol. 164, 467–476.

Kinch, T. L., Gatterick, J. A., Solenberger, P. J., Pfluger, P. T., Czuczman, M. S., Boudinot, P. D., Berrier, C. E., Hales, J. W., Heiman, M. L., Lustig, R. H., Greenway, F., Velasquez-Jimenez, T. A., Willency, J. A., Schurmann, S. A., El-Vakidy, S. S., Oliveri, M. C., Johnson, R. H., Mahata, S. K., O’Connor, D. P., Howard, A. D., Witcher, D. R., Gordon, H. M., Gaylinn, B. D., and Thomas, M. O. (2008). Novel ghrelin antisense provides evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J. Clin. Endocrinol. Metab. 93, 1985–1987.

Kiyosue, T., Zhou, Y. Z., Zhang, G. G., Cai, Y., Yuan, X. Z., Xiong, J. Q., Shi, Y., Tang, C. S., Yin, X. H., and Qu, Y. P. (2010). Cortistatin antisense vacuolar protein sorting (Vps34) gene deletion in rats. Regul. Pept. 159, 35–45.

Kong, A. H., Chau-Bac-Bien, T., Guillaume, D. J., Govek, E. E., Melmon, L. K., Qu, Y., Dintenfass, P. S., and Yen, J. S. (1984). Improved insulin sensitivity and metabolic flexibility in ghrelin receptor knockout mice. Regul. Pept. 30, 147–155.

Lanctot, B. G., Gurney, K. W., Vila-Munoz, P., Gunther, D. M., Schramm, D. T., Smith, D. D., Smith, W. D., Noble, N., Warr, G., Berg, W., Moloney, J., Boudinot, J. Z., Hwu, W., and Hohfeld, J. K. (2006). A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int. J. Obes. (Lond.) 30, 151–159.

Larson, M. A., Gettler, T. L., Porte, Jr., D., Brancati, F. L., Banach, M., Dufour, S., Buse, J. M., Bailey, S. A., English, D., Eckel, J. R., and Thompson, P. F. (2009). Prospective markers of diabetes: ghrelin increases from obesity to type 2 diabetes. Diabetes Care 32, 1944–1950.

Leclercq, B., Desbois, M., Elgueta, M., Corre, D., Laurent, F., Efendji, O., Bellet, A., Guillem, D., and Michaud, S. (2010). Ghrelin is associated with insulin resistance, hyperinsulinemia, and the prevalence of type 2 diabetes. Diabetologia 53, 2784–2790.

Levy, S. M., Kivlighn, E., Horlick, S., Kauma, H., Kauwski, Y. A., and Utkin, O. (2003). Low plasma ghrelin is associated with insulin resistance, hyperinsulinemia, and the prevalence of type 2 diabetes. Diabetologia 46, 890–895.

Levy, S. M., Kivlighn, E., Horlick, S., Kauma, H., Kauwski, Y. A., and Utkin, O. (2003). Low plasma ghrelin is associated with insulin resistance, hyperinsulinemia, and the prevalence of type 2 diabetes. Diabetologia 46, 890–895.
Saad, M. F., Bernabela, B., Heu, C. M., Joungsuda, S., Sahmi, F., Kagose, E., and Beydoun, B. (2002). Insulin regulates plasma ghrelin concentra- tion. J. Clin. Endocrinol. Metab. 87, 3997–4000.

Salmi, J., Jedin, S., Olefors, T., Dagn, A. E., Akin, K. O., Guand, S. C., Carst, Z., and Oessman, M. R. (2011). D- induced obesity suppresses ghrelin in rat gastrointestinal tract and serum. Mol. Cell. Endocrinol. 355, 299–308.

Sakata, I., Yang, J., Lee, C. E., Culon-Lawrence, S., Kermody, S. A., Elmgquist, J. K., and Zigman, W. (2005). Neuropeptides as pleiotropic statin variants in the frog brain: a novel developmentally regulated ghrelin gene family. J. Neuroendocrinol. 17, S18–S23.

Seim, I., Amorini, L., Palopoli, C., Certo, S., Chopin, L. K., and Herington, A. C. (2010). Ghrelin gene-related peptide multia- tions and endocrine carcinoma modulators in health and disease. Clin. Exp. Pharmacol. Physiol. 37, 125–131.

Seim, I., Gallo, C., Herington, A. C., Mornet, E., and Zierath, J. (2010). Reduced genomic structure of the human ghrelin gene and identification of novel exons, alternative splice variants and natural antisense tran- scripts. BMC Genomics 11, 289.

Seim, I., Mornet, E., Zierath, J. R., and Seim, I. (2011). The effect of feeding frequency on insulin and ghrelin responses in human subjects. Br. J. Nutr. 105, 810–819.

Seim, I., Mornet, E., Zierath, J. R., and Seim, I. (2011). The effect of feeding frequency on insulin and ghrelin responses in human subjects. Br. J. Nutr. 105, 810–819.

Seim, I., Mornet, E., Zierath, J. R., and Seim, I. (2011). The effect of feeding frequency on insulin and ghrelin responses in human subjects. Br. J. Nutr. 105, 810–819.
